|1.||Machida, Yoshiharu: 3 articles (06/2008 - 08/2007)|
|2.||Onishi, Hiraku: 3 articles (06/2008 - 08/2007)|
|3.||Oosegi, Tomoko: 3 articles (06/2008 - 08/2007)|
|4.||McGinity, James W: 3 articles (08/2007 - 10/2003)|
|5.||Jain, Sanjay K: 2 articles (01/2016 - 02/2010)|
|6.||Cruz, Letícia: 2 articles (04/2014 - 08/2010)|
|7.||Tavakoli, Naser: 2 articles (01/2012 - 01/2009)|
|8.||Varshosaz, Jaleh: 2 articles (01/2012 - 01/2009)|
|9.||Chandran, Sajeev: 2 articles (12/2011 - 04/2011)|
|10.||Greinwald, R: 2 articles (11/2011 - 04/2006)|
02/01/1992 - "Eudragit S-coated prednisolone metasulphabenzoate may be a useful treatment for extensive ulcerative colitis, without risk of systemic steroid side-effects."
11/01/2004 - "The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis."
02/01/2000 - "Twenty-two healthy volunteers (12 males, aged 22-47 years), and 10 patients (6 males, aged 33-73 years) with active left-sided ulcerative colitis ingested a Eudragit-coated gelatine capsule containing 111In-labelled amberlite resin on four successive days. "
02/01/1992 - "Prednisolone metasulphabenzoate coated with Eudragit S (30-60 mg daily) was then administered for 12 weeks to 12 patients with colonoscopically proven extensive ulcerative colitis in relapse. "
02/01/1992 - "An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use."
|2.||Crohn Disease (Crohn's Disease)
08/01/1992 - "It is concluded that oral 5-ASA coated with Eudragit S (Rohn Pharma GmbH, Wieterstadt, Germany), 2.4 g daily, is safe and seems superior to placebo in preventing or delaying clinical relapse in Crohn's disease, especially in milder cases and in ileal disease."
11/01/1999 - "Clinical efficacy has been demonstrated for Eudragit-L-coated tablets even at a low dose of 1-1.5 g 5-ASA/day in the maintenance treatment of remission of Crohn's disease. "
11/01/1999 - "4.5 g Eudragit-L-coated 5-ASA tablets are almost equally as potent as glucocorticosteroids for the treatment of active Crohn's disease. "
07/01/1999 - "In conclusion, intraluminal pH is not decreased by inflammatory changes in Crohn's disease and ulcerative colitis, allowing eudragit-coated pH-controlled-release formulations of mesalazine to dissolve in diseased areas also."
06/29/2007 - "From the results of this investigation, the application of double microencapsulation technique employing PLGA matrix and Eudragit S-100 coating shows promise for site specific and controlled delivery of budesonide in Crohn's disease."
01/01/2009 - "Results showed that Eudragit L30D-55 with 3% weight gain accompanied with TEC produced suitable enteric coated pellets."
06/05/2008 - "A lag time could therefore be controlled by manipulating both the theoretical weight gain of the beads and the concentration of Eudragit NE 30D in the blend."
10/02/2003 - "In order to pass the USP enteric test, the solution-layered and wet-mass extruded pellets required 35 and 25% weight gain of Eudragit L 30D-55, respectively. "
09/01/2007 - "As far as the three coated layers were concerned, the outer layer was coated with Eudragit L30D-55 for protection against gastrointestinal juices, the intermediate layer was coated with ethylcellulose (EC) to inhibit drug release during passage through the small intestine, and the inner film was coated with pectin for swelling and enzyme-degradation, which required a 30, 10, and 12% weight gain, respectively. "
01/01/2015 - "Eudragit FS 30D content, coating weight gain, tablet hardness and pellet size were chosen as influential factors to investigate the properties and drug release behavior of tablets. "
|4.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
03/01/1994 - "Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events."
10/01/1993 - "Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. "
06/01/1991 - "An Eudragit-L coated oral 5-aminosalicylic acid (5-ASA; mesalazine) product (Mesasal), has been formulated to deliver 5-ASA to the distal small bowel and colon for the treatment of inflammatory bowel disease. "
10/01/1990 - "An Eudragit-L coated oral 5-aminosalicylic acid (5-ASA; mesalazine) product (Mesasal), has been formulated to deliver 5-ASA to the distal small bowel and colon for the treatment of inflammatory bowel disease. "
08/01/1989 - "An Eudragit-L coated oral 5-aminosalicylic acid (5-ASA; mesalazine) product (Mesasal), has been formulated to deliver 5-ASA to the distal small intestine and colon for the treatment of inflammatory bowel disease. "
01/01/2011 - "The efficacy of the optimized formulation (containing 50% lactulose coated with Eudragit E (30% w/w) and Eudragit FS 30D (12% w/w)) was evaluated against 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats. "
06/24/2008 - "Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis."
02/04/2008 - "Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis."
|10.||polylactic acid-polyglycolic acid copolymer (PLGA)